Biocon: India’s Biotech for Better Living

Biocon isn’t just a startup—it’s one of India’s first success stories in biotechnology. Founded in 1978 by Kiran Mazumdar-Shaw in Bangalore, Biocon began as an industrial enzyme company but evolved into a global biopharma leader. With a deep focus on affordable innovation, it now delivers life-saving treatments in diabetes, cancer, and autoimmune diseases to millions—many of whom are in underserved markets like India.

Kiran Mazumdar-Shaw, one of India’s most respected entrepreneurs, started Biocon with just ₹10,000 and a rented garage. Her mission was clear: build a biotech company in India that could match global standards and focus on affordable medicines.

BIOCON Founder: Kiran Mazumdar-Shaw

Key Offerings & Impact

• Biosimilars: Biocon is India’s largest maker of biosimilar drugs, with over 9 FDA-approved products.

• Insulin for India: Biocon supplies affordable insulin to over 2 million diabetes patients across India every year.

• Global Footprint: Biocon exports to 120+ countries, with research and manufacturing based in India.

• Research & Innovation: Invests ₹1,000+ crore annually in R&D and was the first Indian company to get FDA approval for a biosimilar monoclonal antibody.

  
  

Delhi Connection

Though based in Bangalore, Biocon’s impact in Delhi is visible through:

• Distribution of biosimilars in major hospitals like AIIMS and Fortis.

• Joint projects with Delhi-based research labs and CSIR institutes.

• Making life-saving drugs available through Delhi’s government health schemes.

Statistics That Stand Out

• 5,000+ employees in India.

• ₹10,000+ crore annual revenue (FY24).

• Partnerships with Mylan, Viatris, and global pharma giants.

• Helped reduce the cost of cancer treatment in India by 40% via biosimilars.

  
  

Challenges and Growth Plans

Biocon faces hurdles in regulatory approvals, R&D costs, and competition from big pharma. However, its acquisition of Viartis’ biosimilars business in 2022 strengthened its position in global markets. Plans are underway to launch more targeted therapies and expand into gene-based treatments.

Conclusion

Biocon is proof that Indian biotech can be both innovative and affordable. It continues to inspire startups while expanding access to life-saving therapies, both in India and around the world

Register for our Student Entrepreneurs Bootcamp here and win the golden opportunity to grow your business into an upcoming Unicorn!

Share Biocon's story to your friends on LinkedIn or Facebook